Congenital deficiency in alpha-fetoprotein is a rare genetic condition present from birth. People with congenital deficiency in alpha-fetoprotein often have no clear symptoms and may feel well. Doctors may find it during pregnancy testing or blood work, and the medical term refers to very low alpha‑fetoprotein levels. It is lifelong, and not everyone will have the same experience. There is no specific cure, but treatment usually focuses on monitoring and addressing any related health needs, and most people have a normal life span.
Overview
Congenital deficiency in alpha-fetoproteinSymptoms
Most people with congenital deficiency in alpha-fetoprotein have no noticeable signs. It’s usually found on a blood test showing very low or undetectable AFP. The condition can make pregnancy screening and certain liver or cancer marker tests harder to interpret.
Outlook and prognosis
Most people with congenital deficiency in alpha-fetoprotein stay healthy, and life expectancy is usually typical. The main consideration is test interpretation: AFP-based screening in pregnancy, liver checks, or tumor markers may read unusually low. Doctors often note this once and adjust future testing.
Causes and risk factors
Usually caused by pathogenic changes in the AFP gene, typically inherited in an autosomal recessive pattern. Risk rises with parental carrier status, consanguinity, or affected siblings. Environmental or lifestyle factors are not known to cause congenital deficiency in alpha‑fetoprotein.
Genetic influences
Genetics play a central role in congenital deficiency in alpha-fetoprotein, which typically stems from inherited variants in the AFP gene. Most cases follow autosomal recessive patterns. Genetic counseling and, when appropriate, family testing can clarify risks for relatives.
Diagnosis
Doctors suspect it when alpha-fetoprotein (AFP) levels are consistently undetectable on blood tests. Confirmation relies on repeat assays and genetic tests of the AFP gene; this supports the genetic diagnosis of Congenital deficiency in alpha-fetoprotein.
Treatment and drugs
Treatment for congenital deficiency in alpha‑fetoprotein focuses on what’s present, not the lab value itself. Care often includes regular checkups, tailored monitoring in pregnancy, and alternative liver or tumor surveillance strategies when AFP can’t be used. Genetic counseling may be offered for family planning and interpretation of results.
Symptoms
Most people with Congenital deficiency in alpha-fetoprotein feel well, and it’s usually noticed on a blood test rather than through symptoms. Clinicians call this congenital alpha-fetoprotein deficiency, which means AFP (a blood protein mainly made before birth) is very low or absent from birth. Day to day, this rarely changes how someone feels, but it can affect how certain lab tests are interpreted. It matters most in pregnancy screening and in situations where AFP is used as a tumor marker.
Early features of Congenital deficiency in alpha-fetoprotein are often minimal or not noticeable. Most people feel healthy and develop typically. Many only learn about it after a routine blood test.
Blood tests show very low or undetectable alpha-fetoprotein. This finding is lifelong and stable. AFP is a blood protein that’s mostly produced before birth.
During pregnancy with a fetus affected by Congenital deficiency in alpha-fetoprotein, the parent’s AFP screen can be unexpectedly low. That can flag a higher calculated risk for chromosome conditions even when the baby is healthy. Ultrasound and diagnostic tests can help clarify results.
AFP-based cancer monitoring may not work in people with Congenital deficiency in alpha-fetoprotein. Levels may stay low even if a liver cancer or certain testicular or ovarian tumors are present. Care teams use other markers and imaging instead.
How people usually first notice Congenital deficiency in alpha-fetoprotein?
Parents and doctors usually first notice signs during pregnancy, when a routine blood test called the maternal serum alpha‑fetoprotein (MSAFP) screen shows unusually low AFP levels for the gestational age, or when ultrasound findings don’t match expected AFP results; these are often the first signs of congenital deficiency in alpha‑fetoprotein. After birth, many babies appear healthy, and the condition may only come to light if AFP is checked for other reasons, such as evaluating liver or germ cell tumors where AFP would typically be elevated but isn’t. In families with a known history, targeted testing during pregnancy or early childhood is how congenital AFP deficiency is first noticed.
Types of Congenital deficiency in alpha-fetoprotein
Most people learn about congenital deficiency in alpha‑fetoprotein (AFP) after a pregnancy blood test shows unusually low AFP levels without other clear causes. In daily life, this usually doesn’t cause symptoms itself; AFP is a blood protein, not a hormone that drives body changes. Variations mainly reflect why AFP is low—differences in the AFP gene, how the gene is switched on, or lab/inherited factors that affect the test result. Clinicians often describe them in these categories:
AFP gene variants
Changes within the AFP gene lead to very low or undetectable AFP from birth. People usually feel well and have no AFP‑related symptoms. Family testing may show the same pattern in relatives.
Promoter/regulatory variants
Changes in the gene’s on–off switches reduce AFP production. Lab results show consistently low AFP, but everyday health is typically unaffected. Genetic testing may pinpoint the regulatory region involved.
Benign hereditary low AFP
Familial low AFP occurs without disease in other organs. Several relatives may share low AFP levels on routine labs. Not everyone will experience every type.
Analytical or biological mimics
Some results look like low AFP due to assay interference or sample issues. Repeat testing or a different lab method can clarify the true level. Confirming the cause helps avoid unnecessary worry about types of congenital deficiency in alpha‑fetoprotein.
What genetics can tell you about symptoms
Some people with certain AFP gene changes have very low or undetectable alpha-fetoprotein, which can lead to no pregnancy-related AFP rise and may cause confusing prenatal screening results. Others have milder variants, showing slightly reduced AFP without symptoms or health problems.
Causes and risk factors
The main cause is a change in the AFP gene that lowers or blocks alpha-fetoprotein production before birth. These gene changes are often inherited from both parents who each carry the same change, and they can sometimes arise for the first time. Some risks are written in our DNA, passed down through families. Risk factors for Congenital deficiency in alpha-fetoprotein include a family history, two carrier parents, and parents who are related by blood. Lifestyle and environmental exposures do not cause the condition, but they mainly affect overall health rather than the genetic risk.
Environmental and biological risk factors
Congenital deficiency in alpha-fetoprotein is a rare finding present from birth, most often identified through blood testing rather than symptoms. Doctors often group risks into internal (biological) and external (environmental). At this time, no single pregnancy exposure or medical condition has been shown to reliably increase the chance of this deficiency, but the elements below outline what is and isn’t linked.
No confirmed environmental exposures have been tied to congenital deficiency in alpha-fetoprotein. Studies to date have not shown a consistent association with air pollution, radiation at everyday levels, or common chemical exposures.
Common maternal medical conditions (such as high blood pressure or diabetes) have not been shown to increase risk. Current evidence does not support a reliable link between these conditions and this deficiency.
Typical infections in pregnancy, when managed, have not been linked to higher risk. No specific infection has been consistently associated with this deficiency.
Differences in placental function can change how much AFP appears in the mother’s blood, but this does not mean the baby has congenital deficiency in alpha-fetoprotein. This distinction matters when interpreting screening results.
Genetic risk factors
Congenital deficiency in alpha-fetoprotein usually traces back to changes in the AFP gene that reduce how much of this fetal protein is made or alter its structure. Some risk factors are inherited through our genes. Understanding the genetic causes of congenital deficiency in alpha-fetoprotein can help families interpret screening results and consider testing. Inheritance is typically autosomal recessive, meaning the condition appears when two non-working copies are passed to a child.
AFP gene variants: Changes in the AFP gene can prevent the protein from being built correctly or from being released into the bloodstream. This can cause congenital deficiency in alpha-fetoprotein from birth. Different variants can have stronger or milder effects.
Regulatory-region changes: Alterations in control regions near the AFP gene can turn down gene activity during fetal life. This reduces AFP levels even when the coding part of the gene is unchanged. These regulatory changes can contribute to congenital deficiency in alpha-fetoprotein.
Assay-escape variants: Some AFP gene changes alter the protein’s surface so standard lab tests do not recognize it. Tests may read AFP as undetectable even though a modified form is present. This can mimic congenital deficiency in alpha-fetoprotein on screening.
Autosomal recessive pattern: Most cases occur when a child inherits one non-working AFP gene variant from each parent. Each pregnancy between two carriers has a 25% chance of congenital deficiency in alpha-fetoprotein. Siblings may have different outcomes by chance.
Carrier parents: People who carry one AFP gene variant are typically healthy and unaware of it. When both partners are carriers, their children have a higher chance of congenital deficiency in alpha-fetoprotein. Carrier testing can clarify this risk ahead of pregnancy.
Family history: A known AFP gene change in a sibling or close relative raises the chance that others in the family may carry it. Targeted genetic testing for the family’s specific variant can identify carriers. This helps clarify who is at risk for congenital deficiency in alpha-fetoprotein.
Shared ancestry or relatedness: Parents who are related by blood or come from the same small, isolated community are more likely to carry the same rare AFP variant. This increases the chance a child will inherit two copies and develop congenital deficiency in alpha-fetoprotein.
Lifestyle risk factors
Congenital deficiency in alpha-fetoprotein is not caused by lifestyle, but daily habits can influence how easily the condition is monitored and how complications are prevented, especially for liver health and pregnancy care. In pregnancy, standard AFP-based screening is unreliable, so proactive choices help clinicians use other tools effectively. Protecting liver health is also important because AFP cannot be used as a tumor marker, making prevention even more valuable. Below are examples of how lifestyle affects Congenital deficiency in alpha-fetoprotein.
Regular or heavy drinking increases liver inflammation and scarring. Preserving liver health is especially important when AFP cannot be used for tumor surveillance.
Diets high in added sugars and refined carbs raise fatty liver risk. Avoiding fatty liver reduces future reliance on surveillance tools that are less informative without AFP.
Low physical activity worsens insulin resistance and fatty liver risk. Consistent exercise helps protect liver function when AFP-based monitoring is unavailable.
Not taking folic acid before and early in pregnancy raises neural tube defect risk. This is crucial when maternal AFP levels are unreliable for screening.
Risk prevention
Congenital deficiency in alpha-fetoprotein is a genetic condition, so you can’t prevent the condition itself, but you can prevent confusion and unnecessary procedures that may happen because standard tests expect normal AFP levels. There are typically no early symptoms of congenital deficiency in alpha-fetoprotein; prevention focuses on clear documentation and choosing the right tests in pregnancy and later life. Knowing your risks can guide which preventive steps matter most. Planning ahead with your care team helps avoid misread lab results and keeps care on track.
Meet with a genetics professional to confirm the type of inheritance and discuss chances for future children. This can include reviewing test options for you and, if relevant, your partner.
During pregnancy, rely on detailed ultrasound and cell-free DNA testing rather than AFP-based blood screening. This reduces false alarms that can occur when the fetus has congenital deficiency in alpha-fetoprotein.
Ask your clinic to flag your chart that AFP is naturally very low or absent. This helps labs and clinicians interpret results correctly across future pregnancies and other care.
If cancer screening or follow-up is ever needed, plan to use imaging and other blood markers instead of AFP. This prevents missed signals because congenital deficiency in alpha-fetoprotein keeps AFP low even when it’s usually expected to rise.
Transmission
Congenital deficiency in alpha-fetoprotein is not contagious; it can’t be caught or spread between people. In most families, this rare condition follows an autosomal recessive pattern—both parents carry a single, silent change in the AFP gene and, with each pregnancy, there’s a 25% (1 in 4) chance a child will inherit both copies and have the condition. This is how congenital deficiency in alpha-fetoprotein is inherited, though once in a while it may result from a new genetic change in the child. Carriers are healthy and typically unaware, and everyday contact, breastfeeding, or blood exposure do not transmit it.
When to test your genes
Consider genetic testing if alpha‑fetoprotein (AFP) is unexpectedly very low on repeated blood tests without another clear cause, especially with a family history of similar findings or related pregnancy screening anomalies. Testing can confirm a hereditary pattern and guide monitoring for liver, testicular, or ovarian conditions. Discuss timing with a genetics professional before pregnancy planning or major evaluations.
Diagnosis
Congenital deficiency in alpha-fetoprotein is usually suspected when routine blood work shows very low or undetectable AFP levels at times of life when AFP is typically present, and then confirmed with targeted testing. Doctors look closely at the clinical context to make sure the result fits the person’s age and situation, and that a lab issue isn’t creating a false reading. Family history is often a key part of the diagnostic conversation. Some learn of this condition during pregnancy screening when AFP levels do not match expected ranges and the fetus appears otherwise well on ultrasound.
A standard blood test shows persistently very low or undetectable AFP when it would usually be measurable. Results are interpreted using age- and pregnancy-specific reference ranges.
The same sample may be rechecked and a new sample tested with a different method to rule out lab interference. This step helps ensure the low AFP result is accurate.
Doctors review health history, medications, and timing of the test to exclude common explanations for unexpected AFP values. They also look for clinical features that would suggest other liver or germ cell conditions.
During maternal serum screening, an unexpectedly low AFP with normal ultrasound can point to fetal AFP deficiency. From here, the focus shifts to confirming or ruling out possible causes.
Stages of Congenital deficiency in alpha-fetoprotein
Congenital deficiency in alpha-fetoprotein does not have defined progression stages. It’s typically a lifelong lab finding rather than something that gets worse, and most people have no symptoms—there are usually no early symptoms of congenital deficiency in alpha-fetoprotein. Diagnosis is based on very low or undetectable AFP on repeated blood tests, sometimes first noticed during pregnancy screening or routine liver checks, while other causes and lab error are ruled out. Many people feel reassured knowing what their tests can—and can’t—show.
Outlook and prognosis
Looking at the long-term picture can be helpful. For most people with congenital deficiency in alpha-fetoprotein (AFP), the outlook depends less on the low AFP itself and more on whether there are associated genetic conditions. Some individuals have isolated low or undetectable AFP with no symptoms and live typical lifespans. Others have AFP deficiency as part of a broader syndrome, which can influence growth, development, or organ health and, in those cases, overall prognosis follows the underlying condition rather than the AFP level.
Prognosis refers to how a condition tends to change or stabilize over time. Isolated congenital deficiency in alpha-fetoprotein usually stays stable and does not progress, and it rarely causes day-to-day problems. Mortality is not increased when AFP deficiency is truly isolated. The main practical issue is that very low or absent AFP can mask certain lab signals later in life, such as during pregnancy screening or liver tumor monitoring, so care teams may use alternative tests and imaging to avoid missed diagnoses.
Everyone’s journey looks a little different. If AFP deficiency is linked to a known genetic change, doctors may recommend periodic check-ins tailored to that gene’s risks; if no other findings are present, routine health care is typically enough. Early care can make a real difference if any associated features are detected in childhood, supporting speech, movement, learning, or organ function as needed. Talk with your doctor about what your personal outlook might look like, and ask how to interpret tests that normally rely on AFP. If you’re pregnant or planning pregnancy and have AFP deficiency, let your prenatal team know up front; they can adjust screening so early symptoms of congenital deficiency in alpha-fetoprotein do not get overlooked in lab reports.
Long-term effects
Congenital deficiency in alpha-fetoprotein (AFP) is a rare inherited trait where AFP levels remain extremely low or undetectable throughout life. Most people with this trait have typical growth, learning, and day-to-day health. It’s important to remember that “long-term” doesn’t always mean “progressive.” There are typically no early symptoms of congenital deficiency in alpha-fetoprotein, but the low AFP level can affect certain lab tests used in pregnancy and cancer care.
In congenital deficiency in alpha-fetoprotein, AFP levels stay very low or undetectable at all ages. This is a stable lab trait rather than a disease sign. Doctors may document undetectable AFP on repeated tests.
Most people show normal growth, learning, and physical development. No consistent physical features are tied to the trait. Day-to-day health is usually unchanged.
In pregnancy, serum screening tests that rely on AFP can read low regardless of the baby’s health. This can reduce the ability of these tests to flag open neural tube defects or abdominal wall defects. AFP-based portions of these screens may be uninterpretable.
AFP used as a tumor marker may not rise even if a related cancer is present. This makes AFP results unreliable for detecting or tracking liver or yolk sac tumors. In these settings, AFP numbers do not reflect disease activity.
How is it to live with Congenital deficiency in alpha-fetoprotein?
Living with congenital deficiency in alpha-fetoprotein (AFP) often means feeling well day to day, because many people have no symptoms and discover it only through blood tests done in pregnancy or for liver checks. The main adjustment is practical: test results that normally use AFP as a marker can be confusingly low or “negative,” so you and your clinicians may rely on alternative markers or imaging to avoid missed signals during prenatal screening or liver evaluation. Family members and partners may feel anxious when results look unusual, but clear documentation of the baseline low AFP and a plan for future testing usually reduces worry. Keeping a copy of prior lab results and a brief note from your clinician helps prevent repeated alarms and makes routine care smoother.
Treatment and drugs
Treatment for congenital deficiency in alpha-fetoprotein focuses on managing any related health issues rather than replacing alpha-fetoprotein itself, because there’s no approved medicine to restore this protein. Care usually centers on monitoring growth, development, and, if present, associated features like liver function changes, fertility concerns, or pregnancy-related risks; your doctor may suggest periodic blood tests and imaging based on your personal history. Although living with congenital deficiency in alpha-fetoprotein can feel overwhelming, many people manage their symptoms and live fulfilling lives. Treatment plans often combine several approaches, such as targeted care for liver or reproductive health, vaccinations and infection prevention if needed, and genetic counseling for family planning. Ask your doctor about the best starting point for you, and whether referral to a specialist center or a clinical geneticist could help tailor your care.
Non-drug treatment
For many living with congenital deficiency in alpha-fetoprotein, the focus is practical planning rather than medicine. There are often no early symptoms of congenital deficiency in alpha-fetoprotein, but the condition can change how certain lab tests are read in pregnancy or cancer care. Non-drug treatments often lay the foundation for day-to-day care by making sure teams use the right screening tools and avoid confusion. Most people do well with clear documentation, thoughtful prenatal screening choices, and coordinated follow-up.
A genetics professional can explain inheritance, testing options, and what the condition means for you and your family. This visit also covers how the deficiency may affect lab-based screening in pregnancy or tumor monitoring later in life.
If you are pregnant or planning pregnancy, your obstetric team can use ultrasound and other screening methods that do not rely on AFP. A detailed anatomy ultrasound around 18–22 weeks can help screen for neural tube and other structural differences.
Keep a clear note in your medical record and carry a summary so labs know AFP results may be uninterpretable. This simple step helps prevent false alarms or missed findings.
If cancer screening or follow-up is needed for other reasons, your team can prioritize imaging and alternative blood markers instead of AFP. This ensures monitoring remains accurate and tailored to you.
Your genes may have an impact on how drugs work for you
Genes can change how your body absorbs, breaks down, and responds to medicines, so doses or drug choices may need adjustment. For people with congenital alpha-fetoprotein deficiency, clinicians may tailor therapies and monitoring based on genetic testing to improve safety and effectiveness.
Pharmacological treatments
There is no proven medicine that replaces alpha-fetoprotein or directly treats congenital deficiency in alpha-fetoprotein. Most people with this condition do not need drug therapy, and routine health care is usually enough. Because early symptoms of congenital deficiency in alpha-fetoprotein are usually absent, treatment focuses on accurate diagnosis and avoiding unnecessary medications. During pregnancy in affected families, standard AFP-based screening may read lower than expected, which changes test interpretation—not treatment.
There is no drug that replaces alpha-fetoprotein or reverses the genetic cause. Routine monitoring is recommended rather than disease-directed medication.
If unrelated health issues occur, doctors may use standard medicines for those specific problems. Drugs that target symptoms directly are called symptomatic treatments. Treatment choices should match the actual diagnosis at hand.
In families with this condition, maternal blood AFP screening can appear unusually low. This affects how tests are interpreted, not the use of medicines.
There is no role for supplements or drugs aimed at “raising AFP.” Check with your clinician before starting any product marketed to change fetal protein levels.
Genetic influences
In many cases, this rare finding is due to a change in the AFP gene that reduces or turns off production of the alpha-fetoprotein protein before birth. Congenital deficiency in alpha-fetoprotein often follows an autosomal recessive pattern—both parents carry one silent copy, and a child who inherits both copies has very low or undetectable AFP. Family history is one of the strongest clues to a genetic influence. Even within one family, AFP levels can differ, and many people feel well; early symptoms of congenital deficiency in alpha-fetoprotein are often minimal or not noticeable. Because doctors use AFP measurements in pregnancy screening and in some liver or tumor monitoring, an inherited low AFP can lead to misleading test results rather than health problems. Genetic counseling and, when appropriate, testing can confirm the cause, guide how to interpret lab reports, and help relatives understand their chances.
Is Congenital deficiency in alpha-fetoprotein genetic?
Genetics play a central role in congenital deficiency in alpha-fetoprotein, which typically stems from inherited variants in the AFP gene. Most cases follow autosomal recessive patterns. Genetic counseling and, when appropriate, family testing can clarify risks for relatives.
Pharmacogenetics—how genetics influence drug effects
In congenital deficiency in alpha-fetoprotein (AFP), the genetic change lowers or eliminates AFP in the blood, so care focuses on choosing the right tests rather than giving a medicine to “replace” it. This mostly affects situations where AFP would guide care—such as pregnancy screening or tracking certain liver or germ cell tumors—so doctors rely on ultrasound, imaging, or other blood markers instead. The AFP gene doesn’t control the enzymes that break down medicines, so congenital deficiency in alpha-fetoprotein by itself doesn’t usually change how most drugs are processed or the dose you need. If treatment is needed for an unrelated condition, your care team may still personalize dosing using general pharmacogenetic guidance that applies widely, such as for some pain medicines, antidepressants, or chemotherapy. Genetic testing can sometimes identify how your body handles certain medicines and suggest safer starting doses. Overall, genetics shapes treatment here by steering testing and monitoring choices, while medication response typically follows the usual person-to-person differences.
Interactions with other conditions
For people who also have conditions where AFP is used as a blood marker—such as certain liver or testicular germ cell cancers—this deficiency can make routine monitoring tricky because results may look “normal” even when disease is active. Congenital deficiency in alpha-fetoprotein keeps AFP very low, so doctors may not see the usual rise with active hepatitis, cirrhosis, or some tumors, which can delay follow‑up testing or treatment decisions. Another important aspect is how it may link with other diseases. In pregnancy, screening tests often rely on AFP from the fetus; in families with this rare deficiency, results can be misleading and usually need interpretation by a maternal–fetal medicine specialist or genetic counselor. There’s no strong evidence that the deficiency itself raises the risk of other illnesses, but it can mask lab signals that typically prompt earlier checks, so clinicians often use imaging or alternative markers. Because early symptoms of congenital deficiency in alpha-fetoprotein are often absent, let your care team know about the diagnosis so they can choose the right tests if another condition is suspected.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described newborns who were unexpectedly fragile at birth, only later learning that a key blood protein was missing during pregnancy. Families and communities once noticed patterns in which some pregnancies had very low readings on prenatal blood tests, even when dates were correct and the pregnancy otherwise seemed healthy. These early clues, noticed in routine care, set the stage for understanding congenital deficiency in alpha-fetoprotein.
In recent decades, awareness has grown as prenatal screening became standard in many countries. Alpha‑fetoprotein (often shortened to AFP) is one of the markers checked in the second trimester. When AFP was first adopted for screening in the 1970s and 1980s, very low values raised concerns mainly about lab error, timing, or certain chromosomal conditions. Over time, descriptions became more precise, and doctors began to recognize a small subset of pregnancies where the fetus made little or no AFP for genetic reasons, rather than because of dating or other issues.
Initially understood only through symptoms, later cases were pieced together with modern lab methods, showing that some babies were born healthy despite the lack of this fetal protein, while others had features linked to the underlying genetic cause. As medical science evolved, researchers mapped the genes involved in making and transporting AFP, which helped explain why some families had repeated pregnancies with very low AFP levels despite careful testing. Case reports from different regions gradually formed a clearer picture: this condition is rare, can run in families, and may show up first as an unexpected screening result rather than obvious physical signs.
From early theories to modern research, the story of congenital deficiency in alpha‑fetoprotein reflects how screening tools can reveal hidden biology. What started as puzzling numbers on a lab printout grew into a defined diagnosis once genetic testing and better assays arrived. Not every early description was complete, yet together they built the foundation of today’s knowledge. Now, clinicians understand that very low AFP on prenatal tests can have several explanations, and congenital deficiency is one of them—something to consider carefully, confirm with follow‑up testing, and discuss with families with clarity and reassurance.